249 related articles for article (PubMed ID: 20537457)
1. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
2. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
3. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
4. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
6. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
[TBL] [Abstract][Full Text] [Related]
7. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
Boher JM; Pujol JL; Grenier J; Daurès JP
Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
9. [The changes in serum neuron-specific enolase in patients with small cell lung cancer].
Taitou H; Sakurai M; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ookura H; Saijo N
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3046-9. PubMed ID: 2823722
[TBL] [Abstract][Full Text] [Related]
10. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
[TBL] [Abstract][Full Text] [Related]
11. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
13. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer].
Zych J; Szturmowicz M; Sakowicz A; Słodkowska J; Załeska M; Radzikowska E; Załeska J; Jodkiewicz Z; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 2002; 70(5-6):278-83. PubMed ID: 12518626
[TBL] [Abstract][Full Text] [Related]
14. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
15. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
[TBL] [Abstract][Full Text] [Related]
16. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M
Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical implication of neuron-specific enolase and creatine kinase BB in small cell lung cancer.
Ariyoshi Y; Kato K; Ueda R; Takahashi T; Sato T; Akatsuka H; Kuwabara M; Kito K; Suchi T; Nishimura M
Jpn J Clin Oncol; 1986 Sep; 16(3):213-21. PubMed ID: 3022031
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
19. [The "neuron-specific enolase" tumor marker as a prognostic indicator in small cell bronchial carcinoma].
Hoster M; Kirchheiner T; Rühle KH
Pneumologie; 1995 Aug; 49(8):470-4. PubMed ID: 7479642
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]